ArticleFrontiers in nuclear medicine2025
Comparative dosimetric evaluation of 68Ga-PSMA and 18F-Choline PET/CT imaging in prostate cancer: implications for radiation safety and SUVmax correlation.
Article in Frontiers in nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comparative patient dosimetry for diagnostic PET/CT can guide radiation-safety procedures and tracer selection in prostate cancer. We compared [^68Ga]Ga-PSMA-11 and ^18F-choline PET/CT and examined whether kidney SUVmax predicts patient effective dose (ED). Methods: Prospective single-center study of consecutive men undergoing clinically indicated PET/CT: 70 ^68Ga-PSMA-11 and 70 ^18F-choline examinations (Jan 2022-Dec 2023). Dose-rate measurements were recorded at the injection site and at 1 m, immediately post-injection and at 1 h. ED was derived from literature-based tracer coefficients (h_PSMA-11 = 0.0169 mSv/MBq; h_F-choline = 0.0173 mSv/MBq). Kidney SUVmax was extracted in a subset ( Results: Mean surface dose rate was higher with ^68Ga-PSMA vs. ^18F-choline (4.9 ± 0.8 vs. 4.5 ± 0.7 µSv·h Conclusions: ^68Ga-PSMA yields slightly higher dose-rate readings than ^18F-choline, while overall ED is comparable. These exploratory correlations do not support SUVmax as a stand-alone safety surrogate or outcome predictor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.